Treatment for post-natal depression authorised in UK
The first targeted treatment for post-natal depression (PND) has been authorised for use in the UK through the approval of Biogen’s zuranolone by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Biogen state that the marketing authorisation by the MHRA addresses a critical, unmet need in maternal health due to the current standard of care for PND involving psychological interventions, such as talking therapies and off-label use of antidepressants that that typically take four to six weeks to show effectiveness, and sometimes up to 12 weeks.
PND is a serious medical condition that affects women during late pregnancy and up to 12 months after childbirth.1 The disease mechanism of PND is distinct from other mental health conditions, though symptoms may appear similar to major depressive disorder (MDD) or baby blues.1,8-10 The hormonal and neurochemical changes specific to childbirth trigger different brain mechanisms than those seen in MDD, affecting how the condition develops.8-10
Around 23.8 million women worldwide experience PND every year, with the condition being characterised by persistent sadness, anxiety, a loss of interest or pleasure in daily activities, sleep disturbances and exhaustion, and in some cases, thoughts of self-harm or harm to the baby lasting more than two weeks.
Biogen state that Zuranolone has a mechanism of action that provides rapid relief of depressive symptoms through a 14-day treatment course, with symptom relief seen as soon as day three of treatment. Clinical data show that a 14-day course of oral zuranolone led to rapid, statistically significant, and clinically meaningful improvements in depressive symptoms in women with moderate or severe post-natal depression by day three of the treatment course
Dr Mano Manoharan, Consultant Perinatal Psychiatrist said: “Postnatal depression affects 1 in 10 mothers, sometimes stigma and poor recognition delay the necessary care. This condition impacts not only mothers but also infants and families. Holistic, evidence-based treatments are vital. The introduction of zuranolone offers a fast-acting, targeted breakthrough to support women swiftly and compassionately”.
“This is an important first step in our journey to help address the needs of women experiencing post-natal depression in the UK,” said Kylie Bromley, VP, General Manager UK & Ireland. “We are committed to working with NICE, the SMC and other stakeholders to ensure this treatment becomes accessible to all women who need it. This approval reflects our ongoing drive to make breakthroughs happen in the science of mental health. We are proud to offer a new treatment option developed to help positively impact the lives of women and their families.”
Biogen UK is now collaborating with NICE and the SMC to make zuranolone available on the NHS.
